Cardiff Oncology AI Stock Analysis
Want to see CRDF full AI Analyst Report?
Cardiff Oncology (CRDF) AI Stock Analysis
Cardiff Oncology
(NASDAQ:CRDF)
The score is primarily held down by weak financial performance—large ongoing losses and sustained cash burn that likely require additional funding—despite low leverage. Technicals also remain bearish with the stock trading below key moving averages, partially offset by oversold signals. Valuation support is limited because the company is unprofitable (negative P/E) and provides no dividend yield.
Cardiff Oncology (CRDF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $56.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 592.60K
- Price to Earnings (P/E)
- -1.3
- Beta (1Y)
- 1.42
- Revenue Growth
- 11.58%
- EPS Growth
- 32.14%
- Country
- US
- Employees
- 31
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cardiff Oncology Business Overview & Revenue Model
Company Description
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treatin...
Cardiff Oncology Earnings Call Summary
The earnings call highlighted strong initial clinical data, successful capital raising efforts, and a solid financial position. However, some dependency on future FDA meetings and the early stage of PFS data might pose challenges. Overall, the sentiment is optimistic with clear progress, yet some uncertainties remain.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call, guidance was provided on several key metrics and future plans for the company. The company highlighted an initial data set from the CRDF-004 trial, which showed a 64% overall response rate (ORR) for patients on the 30 mg dose of onvansertib, compared to 33% in the control arm. The trial focuses on first-line RAS-mutated metastatic colorectal cancer (mCRC), and aims to complete enrollment of 90 evaluable patients in early 2025. The company plans to release additional clinical data in the first half of 2025. Financially, Cardiff Oncology reported $91.7 million in cash and short-term investments as of December 31, 2024, following a $40 million capital raise. The company projects that these resources will support operations into the first quarter of 2027, with a quarterly cash burn of $10.3 million in Q4 2024. Additionally, Cardiff Oncology strengthened its intellectual property portfolio with a new patent for onvansertib, expected to expire no earlier than 2043.
Cardiff Oncology Financial Statement Overview
Summary
Income statement and cash flow are very weak for a pre-commercial biotech: minimal and declining revenue ($0.39M TTM) alongside very large losses (net income -$37.7M) and heavy ongoing cash burn (operating/free cash flow about -$39.9M TTM), implying continued funding needs. The balance sheet is low-debt (debt-to-equity ~0.02), but equity has fallen sharply versus prior years, signaling capital erosion/dilution risk.
Income Statement
12Very NegativeBalance Sheet
62PositiveCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 388.00K | 593.00K | 683.00K | 488.00K | 386.00K | 359.00K |
| Gross Profit | 388.00K | 593.00K | 683.00K | 488.00K | 386.00K | 359.00K |
| EBITDA | -37.35M | -44.95M | -45.03M | -41.04M | -38.47M | -27.84M |
| Net Income | -37.66M | -45.85M | -45.43M | -41.44M | -38.70M | -28.29M |
Balance Sheet | ||||||
| Total Assets | 36.41M | 61.88M | 97.19M | 81.64M | 116.19M | 149.54M |
| Cash, Cash Equivalents and Short-Term Investments | 33.79M | 58.30M | 91.75M | 74.82M | 105.27M | 140.82M |
| Total Debt | 265.00K | 832.00K | 1.52M | 2.15M | 2.71M | 3.12M |
| Total Liabilities | 8.32M | 16.50M | 14.24M | 11.90M | 9.85M | 9.13M |
| Stockholders Equity | 28.10M | 45.39M | 82.95M | 69.74M | 106.34M | 140.42M |
Cash Flow | ||||||
| Free Cash Flow | -39.94M | -37.97M | -37.77M | -31.47M | -34.71M | -23.25M |
| Operating Cash Flow | -39.89M | -37.92M | -37.69M | -30.89M | -33.82M | -23.04M |
| Investing Cash Flow | 29.88M | 1.34M | 13.73M | 36.20M | 38.15M | -131.45M |
| Financing Cash Flow | 11.94M | 2.58M | 53.78M | 0 | 75.00K | 35.45M |
Cardiff Oncology Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRDF, the sentiment is Negative. The current price of 0.73 is below the 20-day moving average (MA) of 0.85, below the 50-day MA of 1.05, and below the 200-day MA of 1.35, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 31.27 is Neutral, neither overbought nor oversold. The STOCH value of 10.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRDF.
Cardiff Oncology Risk Analysis
Cardiff Oncology disclosed 64 risk factors in its most recent earnings report. Cardiff Oncology reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksCardiff Oncology Peers Comparison
Overall Rating
ONCY44Neutral- CRDF43Neutral
PYXS41Neutral
AVTX40Underperform
MOLN39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ONCY | 44Neutral | $47.43M | -1.30 | 1020.21% | ― | ― | 2.05% |
| CRDF | 43Neutral | $56.60M | -1.32 | -103.08% | ― | 11.58% | 32.14% |
| PYXS | 41Neutral | $188.98M | -1.22 | -252.36% | ― | 291.42% | 18.90% |
| AVTX | 40Underperform | $445.24M | -2.69 | -34.21% | ― | -69.27% | 66.84% |
| MOLN | 39Underperform | $119.38M | -1.78 | -79.25% | ― | ― | 11.22% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CRDF | Cardiff Oncology, Inc. | 0.73 | -1.33 | -64.76% | |
| ONCY | Oncolytics Biotech | 0.37 | -0.68 | -64.76% | |
| AVTX | Avalo Therapeutics, Inc. | 7.76 | -9.12 | -54.01% | |
| GLSI | Greenwich Lifesciences, Inc. | 14.94 | 6.71 | 81.53% | |
| MOLN | Molecular Partners Ag | 2.94 | -1.32 | -30.99% | |
| PYXS | Pyxis Oncology, Inc. | 1.58 | -3.07 | -66.02% |
Cardiff Oncology Corporate Events
Cardiff Oncology Names Interim CMO Amid Trial Progress
PositiveCardiff Oncology expanded its capital structure on October 22, 2026, by amending its certificate of incorporation in Delaware to increase its authorized common shares to 300 million, a move that can facilitate future financing, partnerships or strate...
Cardiff Oncology Shareholders Approve Expanded Capital Structure
PositiveOn October 22, 2026, Cardiff Oncology, Inc. held a Special Meeting of Stockholders at which 48,084,246 shares of common stock were represented, constituting a quorum for corporate action. Stockholders approved an amendment to the company’s Amended an...
Cardiff Oncology Amends Onvansertib License, Resolves Litigation
PositiveOn September 14, 2026, Cardiff Oncology and Nerviano Medical Sciences agreed to a confidential settlement resolving litigation over inventorship and performance issues tied to their 2017 license for onvansertib, Cardiff’s lead PLK1 inhibitor. The par...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026